BioSpace News Archive

DILIsym Services, Inc.,(NASDAQ: SLP) today announced that the U.S. Food and Drug Administration has secured an annual government license for its flagship QSP (quantitative systems pharmacology) modeling software

Study designed to evaluate X4P-001-IO in expanded range of combination treatment settings to be presented at the Annual Meeting of the Association for Cancer Immunotherapy

Robert J. Rush appointed Vice President, Finance and Chief Financial Officer; Ajay Damani appointed Vice President, Business Unit Leader – Pharmaceutical Technologies; Giuseppe Di Vincenzo named Vice President, Strategy

Webcast Available Through Gilead Corporate Website

- Revenue grew 100% year over year to $6.9 million - Net income of $1.9 million increased 444% year over year; Diluted EPS $0.06 - Adjusted EBITDA of $2.0 million increased 257% year over year - Seventh consecutive quarter of positive net income, 82% gross margin and 28% operating margin

For OTC Ophthalmic Drop Products

--Patient enrollment into the study expected to begin by the end of June 2018--

XtalPi Inc. (“XtalPi”), a computation-driven pharmaceutical technology company, announced today a strategic research collaboration with Pfizer Inc. (“Pfizer”) to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular modeling of drug-like small molecules.

Company expands Integrated Patient Experience Solutions to Los Angeles Market; Brant Heise and Mark Neaman join Board of Directors

Click Therapeutics, Inc., has been awarded a National Institutes of Health (NIH) Small Business Innovation and Research (SBIR) grant through the National Institute of Drug Abuse (NIDA)